Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection.

OBJECTIVE--To study the contribution of the humoral response to HIV-I at seroconversion to disease outcome after 84 months. DESIGN--A retrospective longitudinal study. SETTING--Two haemophilia centres in the United Kingdom. PATIENTS--88 Haemophiliac patients infected with HIV-I for whom sera were available from before seroconversion and in whom clinical follow up data were available. RESULTS--Kaplan-Meier survival analysis showed a significant difference between a high titre (greater than 1600) p24 antibody response at seroconversion and prolonged time before the development of HIV related disease (p = 0.0008). In contrast, higher titres of antibody to gp120 at seroconversion (greater than 25,600) correlated with more rapid clinical deterioration (p = 0.025). CONCLUSIONS--The first humoral response to HIV proteins at seroconversion is associated with clinical outcome; patients with an initial low titre antibody response to the gagp24 protein have a significantly faster rate of progression to CDC stage IV disease. Patients with a high titre p24 antibody response progress to AIDS more slowly, and these data provide an explanation why p24 antigenaemia is not universally detected in patients with AIDS. It is unclear whether the association between a strong initial p24 antibody response and slower progression of HIV disease is causal and if so whether it is due to viral or host factors.

[1]  J. Weber,et al.  Antibodies to HIV-1 nef(p27): prevalence, significance, and relationship to seroconversion. , 1990, AIDS research and human retroviruses.

[2]  J. Habeshaw,et al.  HIV envelope glycoprotein, antigen specific T-cell responses, and soluble CD4 , 1990, The Lancet.

[3]  J. Phair,et al.  A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection A report from the Multicenter AIDS Cohort Study , 1990, The Lancet.

[4]  D. Ho,et al.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1989, The New England journal of medicine.

[5]  A. Collier,et al.  Plasma viremia in human immunodeficiency virus infection. , 1989, The New England journal of medicine.

[6]  R. Mittler,et al.  Synergism between HIV gp120 and gp120-specific antibody in blocking human T cell activation. , 1989, Science.

[7]  D. Montefiori,et al.  Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[8]  F. Ruscetti,et al.  Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping , 1989, Journal of virology.

[9]  F. Ennis,et al.  Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. , 1988, Science.

[10]  R. Siliciano,et al.  Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: Effect of HIV sequence variation and a mechanism for CD4+ cell depletion , 1988, Cell.

[11]  P. Simmonds,et al.  HLA HAPLOTYPE A1 B8 DR3 AS A RISK FACTOR FOR HIV-RELATED DISEASE , 1988, The Lancet.

[12]  R. Chaisson,et al.  Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort , 1988, British medical journal.

[13]  P. Simmonds,et al.  HIV antigen and antibody detection: variable responses to infection in the Edinburgh haemophiliac cohort , 1988, British medical journal.

[14]  M. Youle,et al.  Restriction of sensitivity of HIV-1-antigen ELISA by serum anti-core antibodies. , 1988, AIDS.

[15]  D. Jeffries,et al.  Decline of anti-p24 antibody precedes antigenaemia as correlate of prognosis in HIV-1 infection. , 1987, AIDS.

[16]  M. Leuther,et al.  LONG LATENCY PRECEDES OVERT SEROCONVERSION IN SEXUALLY TRANSMITTED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION , 1987, The Lancet.

[17]  J. Nielsen,et al.  Temporal relation of antigenaemia and loss of antibodies to core antigens to development of clinical disease in HIV infection. , 1987, British medical journal.

[18]  J. Goudsmit,et al.  Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. , 1987, British medical journal.

[19]  H. Jaffe,et al.  Antibody response to human immunodeficiency virus in homosexual men. Relation of antibody specificity, titer, and isotype to clinical status, severity of immunodeficiency, and disease progression. , 1987, The Journal of clinical investigation.

[20]  J. Albert,et al.  HIV ANTIGENAEMIA AND VIRUS ISOLATION FROM PLASMA DURING PRIMARY HIV INFECTION , 1987, The Lancet.

[21]  D. Cooper,et al.  Antibody response to human immunodeficiency virus after primary infection. , 1987, The Journal of infectious diseases.

[22]  J. Goudsmit,et al.  Viral gene expression, antibody production and immune complex formation in human immunodeficiency virus infection. , 1987, AIDS.

[23]  A. Goldstein,et al.  Human immunodeficiency virus contains an epitope immunoreactive with thymosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Tedder,et al.  HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN TWO COHORTS OF HOMOSEXUAL MEN: NEUTRALISING SERA AND ASSOCIATION OF ANTI-GAG ANTIBODY WITH PROGNOSIS , 1987, The Lancet.

[25]  J. Goudsmit,et al.  Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. , 1986, British medical journal.

[26]  Y. Laurian,et al.  SEROLOGICAL MARKERS IN EARLY STAGES OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HAEMOPHILIACS , 1986, The Lancet.

[27]  J. Levy,et al.  Circulating immune complexes in patients with acquired immune deficiency syndrome contain the AIDS-associated retrovirus. , 1986, Clinical immunology and immunopathology.

[28]  K. Steimer,et al.  Differential antibody responses of individuals infected with AIDS-associated retroviruses surveyed using the viral core antigen p25gag expressed in bacteria. , 1986, Virology.

[29]  J. Goudsmit,et al.  Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus. , 1986, British medical journal.

[30]  J. Nielsen,et al.  Variation in human T lymphotropic virus III (HTLV-III) antibodies in homosexual men: decline before onset of illness related to acquired immune deficiency syndrome (AIDS). , 1985, British medical journal.

[31]  J. Groopman,et al.  Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. , 1985, Science.

[32]  H. Joller,et al.  Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS. , 1985, The New England journal of medicine.

[33]  E. M. Briggs,et al.  PREVALENCE OF ANTIBODY TO HUMAN T-LYMPHOTROPIC VIRUS TYPE III IN AIDS AND AIDS-RISK PATIENTS IN BRITAIN , 1984, The Lancet.

[34]  J Schüpbach,et al.  Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS. , 1984, Science.

[35]  J Schüpbach,et al.  Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. , 1984, Science.

[36]  J. Mcnee,et al.  A CONTRIBUTION TO THE STUDY OF WAR NEPHRITIS , 1917, British medical journal.

[37]  R. Redfield,et al.  Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections. , 1986, MMWR. Morbidity and mortality weekly report.